Correo Electrónico
DNINFOA - SIA
Bibliotecas
Convocatorias
Identidad U.N.
Publicado
On a multi-fractional virotherapy model for cancer treatment
Sobre un modelo de viroterapia multifraccional para el tratamiento del cáncer
DOI:
https://doi.org/10.15446/recolma.v60n1.129106Palabras clave:
Oncolytic virotherapy, Modeling, Fractional derivatives (en)Viroterapia oncolítica, Modelagem, Derivadas Fraccionales (es)
Descargas
In this paper, we enhance the oncolytic virotherapy model examined by [23] by incorporating multi-fractional derivatives of the Caputo type, assigning distinct derivative orders to each model variable. We establish the Hadamard well-posedness of the new model and confirm that the solutions remain within the positive half-plane, aligning with the criteria of the modeled problem. Furthermore, we conduct a stability analysis for the equilibrium solutions of these multi-fractional dynamics, demonstrating their dependence on the derivative orders specified in the dynamics. The theoretical insights are supported by numerical simulations.
En este artículo, mejoramos el modelo de viroterapia oncolítica examinado por [23] incorporando derivadas multifraccionales del tipo Caputo, asignando órdenes de derivadas distintas a cada variable del modelo. Establecemos la correcta formulación de Hadamard del nuevo modelo y confirmamos que las soluciones permanecen dentro del semiplano positivo, alineándose con los criterios del problema modelado. Además, realizamos un análisis de estabilidad para las soluciones de equilibrio de estas dinámicas multifraccionales, demostrando su dependencia de los órdenes de derivadas especificados en la dinámica. Los conocimientos teóricos están respaldados por simulaciones numéricas.
Referencias
[1] The analysis of fractional differential equations: An application-oriented exposition using differential operators of caputo type, Springer, 2010.
[2] R. Almeida, Analysis of a fractional seir model with treatment, Applied Mathematics Letters 84 (2018), 56-62.
[3] Z. Bajzer, T. Carr, K. Josic, S. J. Russell, and D. Dingli, Modeling of cancer virotherapy with recombinant measles viruses, Journal of Theoretical Biology 252 (2008), no. 1, 109-122.
[4] Wodarz D., Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents, Hum Gene Ther. 14 (2003), no. 2, 153-159.
[5] E. Dai, Z. Zhu, S. Wahed, Z. Qu, W. J. Storkus, and Z. S. Guo, Epigenetic modulation of antitumor immunity for improved cancer immunotherapy, Molecular cancer 20 (2021), no. 1, 171.
[6] K. Diethelm, A fractional calculus based model for the simulation of an outbreak of dengue fever, Nonlinear Dynamics 71 (2013), no. 4, 613-619.
[7] M. A. Dokuyucu, E. Celik, H. Bulut, and H. M. Baskonus, Cancer treatment model with the caputo-fabrizio fractional derivative, The European Physical Journal Plus 133 (2018), no. 92, 1-6.
[8] M. Ehrlich and E. Bacharach, Oncolytic virotherapy: the cancer cell side, Cancers 13 (2021), no. 5, 939.
[9] J. Gallegos, Stability and applications of multi-order fractional systems, Discrete and Continuous Dynamical Systems Series B 27 (2022), no. 9, 5283-5296.
[10] R. Garrappa, Trapezoidal methods for fractional differential equations: Theoretical and computational aspects, Mathematics and Computers in Simulation 110 (2015), 96-112.
[11] M. Idrees, A. S. Alnahdi, and M. B. Jeelani, Mathematical modeling of breast cancer based on the caputoˆafabrizio fractal-fractional derivative, Fractal and Fractional 7 (2023), no. 11.
[12] N. L. Komarova and Wodarz D, Targeted cancer treatment in silico, Birkhauser, 2014.
[13] P. Kumar, V. S. Erturk, A. Yusuf, and S. Kumar, Fractional time-delay mathematical modeling of oncolytic virotherapy, Chaos, Solitons & Fractals 150 (2021), 111123.
[14] D. Lin, Y. Shen, and T. Liang, Oncolytic virotherapy: basic principles, recent advances and future directions, Sig Transduct Target Ther 156 (2023), no. 8, 1-25.
[15] G. F. Luz and A. De Cezaro, On a mathematical model of the influence of memory on cancer treatment using gene therapy, Ciˆencia e Natura 46 (2024), no. 1, e86886.
[16] M. Tontonoz, Fda approves first in a new class of immunotherapies, Cancer Research Institute, New York, United States, 2015.
[17] J. Malinzi, K. B. Basita, S. Padidar, and H. A. Adeola, Prospect for application of mathematical models in combination cancer treatments, Informatics in Medicine Unlocked 23 (2021), 100534.
[18] Z. Odibat and N. Shawagfeh, Generalized taylorˆas formula, Applied Mathematics and Computation 186 (2007), no. 1, 286-293.
[19] R. Padmanabhan, N. Meskin, and A-E. A. Moustafa, Mathematical models of cancer and different therapies, 1nd ed., Springer, 2021.
[20] H. Rabinowich, M. Banks, T. Reichert, T. Logan, J. Kirkwood, and T. Whiteside, Expression and activity of signaling molecules in t lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy, Clinical cancer research: an official journal of the American Association for Cancer Research 2 (1996), no. 8, 1263-1274.
[21] J. Sotomayor, Licoes de equacoes diferenciais ordinárias, 1nd ed., Instituto de Matemática Pura e Aplicada, CNPq, 1979.
[22] R. Tavoni, Modelos fracionários de terapia gênica para o tratamento do câncer, Ph.D. thesis, Universidade Estadual Paulista Julio de Mesquita Filho, 2023.
[23] R. Tavoni, P. F. A. Mancera, and R. F. Camargo, Stability analysis of a fractional virotherapy model for cancer treatment, Revista Colombiana de Matemáticas 55 (2021), no. 2, 117-196.
[24] A. Tsygvintsev, S. Marino, and D. Kirschner, A mathematical model of gene therapy for the treatment of cancer, Mathematical Methods and Models in Biomedicine, 2012, pp. 367-385.
[25] S. R. et al Volovat, Oncolytic virotherapy: A new paradigm in cancer immunotherapy, Int. J. Mol. Sci. 18 (2024), no. 25, 1-34.
[26] D. Wodarz and N. Komarova, Dynamics of cancer: mathematical foundations of oncology, 1nd ed., World Scientific, 2014.
[27] Y. Zhao, D. H. Lam, J. Yang, J. Lin, C. K. Tham, W. H. Ng, and S. Wang, Retracted article: Targeted suicide gene therapy for glioma using human embryonic stem cell-derived neural stem cells genetically modified by baculoviral vectors, Gene Therapy 19 (2012), no. 2, 189-200.
